Over the past few months, I have been very concerned with a bill that is in the United States Senate called S.959. This bill could drastically impact your ability to have access to compounded medications. The bill would, among other things, identify compounded medications as “new drugs”. “New drugs” fall under the approval of the U.S. FDA and the FDA could block any compound from being made. This would prove to be disastrous to patients who rely on custom medications including those with autism, chronic neuropathic pain, hormonal imbalance, allergies to dyes and fillers and pets to name a few.
There has been much hype and speculation over the fate of S.959. Some outlets reported that S.959 was due for a vote by the U.S. Senate as early as last week. Now it appears that a vote will not occur until after the August recess. The U.S. Senate Health, Education, Labor and Pensions (HELP) committee is still reviewing the bill and had testimony from compounding advocates and adversaries as late as July 31, 2013.
I will do my best to keep you posted if legislation seems imminent. At that time, I will direct you on what course to take to ensure that you maintain access to your compounded medications.
Compounding Legislation Update